Serious Side Effects: Patient Dies in Pfizer Trial

A patient undergoing treatment with Pfizer's hemophilia drug, Hympavzi, has died after experiencing severe side effects. The individual, who was part of a long-term study, passed away on December 14 due to a stroke and subsequent brain hemorrhage.

Pfizer has released a statement indicating that the company, in collaboration with the trial investigator and an independent Data Monitoring Committee, is diligently gathering information to comprehend the multifaceted factors contributing to this event. The Hympavzi therapy, approved in the U.S. last year, is administered as a weekly injection to manage bleeding episodes in hemophilia A or B patients aged 12 and older.

Despite this serious adverse event, Pfizer believes it will not affect the drug's safety profile for other patients. This follows Pfizer's earlier decision this year to halt global development of its hemophilia gene therapy, Beqvez, due to insufficient patient and physician demand.